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Objectives	
Bioorthogonal	 chemistry	 has	 found	 rapidly	 growing	 applications	 in	 the	 field	 of	 molecular	
imaging.	 Considerable	 research	 has	 been	 devoted	 to	 the	 development	 of	 antibody-trans-
cyclooctene	 (TCO)	 conjugates,	 and	 their	 application	 for	 pretargeted	 tumor	 imaging	 has	 been	
reported	under	different	modalities.	However,	 it	has	been	shown	that	TCO	has	 the	 tendency	to	
isomerize	 to	 its	 isomer,	 cis-cyclooctene	 (CCO),	 after	 prolonged	 exposure	 to	 physiological	
conditions.	Given	this,	we	envisaged	a	different	approach	where	the	development	of	more	stable	
[18F]-labeled	 TCOs	 is	 investigated	 for	 pretargeted	 PET	 imaging	 using	 a	 tetrazine-modified	
antibody.		
Methods		
Synthesis	and	characterization	by	NMR	and	high-resolution	mass	spectrometry	of	all	compounds	
was	performed.	Antibody	CC49	(anti	TAG-72)	was	modified	with	an	“in	house”	tetrazine	[1]	and	
analyzed	 by	 SDS-PAGE	 and	 mass	 spectrometry	 to	 determine	 the	 degree	 of	 labeling.	 	 Rate	
constants	 for	the	reaction	between	d-TCO	and	tetrazine	were	measured	by	stopped-flow	under	
aqueous	conditions.	Tracer	in	vitro	stability	was	evaluated	in	PBS	and	mouse	plasma	at	37°C.	In	
vivo	 and	 ex	 vivo	biodistribution	 studies	were	performed	 in	nude	mice	by	 IV	 administration	of	
0.25	mCi	 of	 tracer	 and	 a	whole-body	 dynamic	 (0-60min	 postinjection)	 scans	were	 acquire.	 In	
vivo	 and	 ex	 vivo	 PET/CT	 pretargeted	 imaging	 was	 carried	 out	 in	 human	 colorectal	 tumor	
xenografts	 where	 CC49-tetrazine	 (150µg/100µl)	 and	 CC49	 (100µg/100µl;	 control)	 were	
administered	 IV	 followed	 24h	 later	 by	 [18F]d-TCO	 (0.25	 mCi)	 injection.	 Whole-body	 (60min	
postinjection)	static	scan	was	acquired.		
Results	
The	 novel	 d-TCO	 reacted	 with	 the	 tetrazine	 at	 a	 rate	 constant	 (k2)	 of	 10	 553	 M-1s-1.	 The	
radiolabeling	 of	 d-TCO	 with	 [18F]	 provided	 a	 radiochemical	 yield	 (RCY)	 of	 5.5±0.5	 %	 (decay	
corrected	 to	 EOB)	 and	 >	 98%	 radiochemical	 purity.	 Tracer	 presented	 a	moderate	 lipophilicity	
with	 a	 logD	 value	 1.73±0.01.	 Tracer	 showed	 no	 isomerization	 after	 incubation	 with	 PBS	 and	
plasma	up	to	2h	and	1h,	respectively.	In	vivo	stability	study	showed	that	25%	of	the	tracer	was		
intact	at	5min	p.i.	 In	control	mice	the	tracer	showed	a	mixed	hepatobiliary	and	renal	clearance,	
displaying	 at	 2h	 p.i	 0.44±0.03	 %ID/g	 in	 the	 blood,	 4.85±0.17	 %ID/g	 in	 the	 small	 intestine,	
5.05±0.20	%ID/g	in	the	large	intestine	and	1.31±0.09	%ID/g	in	the	kidneys.	
In	tumor	xenografts	the	average	uptake	in	the	tumors	was	2.1±0.7	%ID/g	at	60min	p.i.	when	pre-
injected	with	 CC49-tetrazine	 and	 0.7±0.1	%ID/g	 p.i.	 when	 pre-injected	with	 CC49	 (control).	 A	
higher	tumor	uptake	could	be	observed	when	the	mice	were	treated	with	CC49-tetrazine	when	
compared	with	the	control.	Furthermore,	tumor-to-muscle	ratio	was	2.5±0.11.		
Conclusions	
We	developed	a	new	 [18F]-d-TCO	 tracer	 that	 showed	good	 stability	with	 fast	 reaction	kinetics	
towards	tetrazine	and	a	favorable	pharmacokinetic	profile	for	pretargeting	approaches.		
We	 were	 also	 able	 to	 demonstrate	 the	 successful	 use	 of	 a	 new	 [18F]-labeled	 d-TCO	 in	 a	 PET	
pretargeted	 imaging	 approach,	 allowing	 visualization	 of	 the	 tumor	 with	 a	 significant	 higher	
uptake	when	 compared	 to	 the	 control.	With	 this	 approach	we	 are	 able	 to	 avoid	 the	prolonged	
exposure	 of	 TCO	 to	 plasma	 proteins	 leading	 to	 its	 deactivation.	 Furthermore,	 thinking	 about	
future	 in	vivo	 applications	having	a	more	hydrophobic-labeled	TCO	can	bring	advantages	when	
cell	membranes	and	blood-brain	barrier	need	to	be	crossed.		
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Fig.1	-	Pretargeted	PET/CT	imaging	of	tumor-bearing	mice	1h	after	injection	of	[18F]d-TCO.	
	
